Silence’s AtuPLEX technology will be central to research efforts.
Silence Therapeutics and AstraZeneca are partnering to develop a range of approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics’ expertise in the delivery of siRNA molecules, in particular its experience with the functional systemic delivery of siRNA in vivo using its AtuPLEX technology.
According to the firms, successful delivery of siRNA molecules to different tissue sites is critical to realize potential of siRNA to treat a broad range of diseases. Under the terms of the agreement, both Silence Therapeutics and AstraZeneca will be allowed to commercialize the delivery systems that they develop together.
Silence Therapeutics will retain the right to sign further delivery deals to capture value from its current AtuPLEX delivery technology as well as any improvements to this technology that it generates either independently or as part of this collaboration.
This new deal is independent of the parties’ three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.